Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin and Exenatide in Type 1 Diabetes
NCT02962492Completed
- Sponsor
- University at Buffalo
- Start
- Nov 2016
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of dapagliflozin in type 1 diabetes mellitus (T1D) (4 arms), sponsored by University at Buffalo. Primary endpoint: Change in Beta-hydroxybutyrate Levels in Blood at 12 weeks. Started Nov 2016; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02962492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02962492.